© 2007 European Society for Medical Oncology
letters to the editor |
Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma
| The first 10% of the full text of this article appears below. |
A 49-year-old male with multiple myeloma was receiving treatment with bortezomib at a dose of 1.3 mg/m2 IV on days 1, 4, 8, and 11, after failed therapies including anakinra, dexamethasone, and thalidomide. During the first cycle of bortezomib, the patient developed bilateral periorbital edema. Over the second cycle skin toxicity progressed into angioedema and
funding
1 Department of Internal Medicine, Roger Williams Medical Center, Providence, RI 02908
2 Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611
3 SERIES Clinic, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611
4 Division of Hematology and Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
* (E-mail: m-lacouture@northwestern.edu)